Updates are available Correction dated 2024-12-19
Click to view Correction: https://doi.org/10.1038/s41421-024-00755-z
-
Authors
Jin, Ying https://orcid.org/0000-0002-6829-7926
Wu, Yuefeng
Reuben, Alexandre https://orcid.org/0000-0003-4510-0382
Zhu, Liang
Gay, Carl M.
Wu, Qingzhe
Zhou, Xintong
Mo, Haomin
Zheng, Qi
Ren, Junyu
Fang, Zhaoyuan
Peng, Teng
Wang, Nan
Ma, Liang
,
Wu, Yuefeng
Fan, Yun
Song, Hai https://orcid.org/0000-0003-3228-6616
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
Chen, Ming
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82272744)
- License Information
-
More Information
Article History
Received: 27 September 2023
Accepted: 23 June 2024
First Online: 4 September 2024
Change Date: 19 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41421-024-00755-z
Conflict of interest
: Dr. Nan Wang is a full-time employee of Cosmos Wisdom Biotech Co. Ltd. J.Z. reports research funding from Merck, Johnson and Johnson, Helius, Summit, and Novartis; honoraria and consulting fees from Bristol Myers Squibb, Johnson and Johnson, Novartis, AstraZeneca, GenePlus, Innovent, Varian, Takeda Catalyst and Hengrui outside the submitted work. Carl Gay declared the speaking engagement of AstraZeneca, BeiGene, MJH, OncLive, PeerView, and Targeted Healthcare and served as the Advisory Board/Steering Committee at Abdera, AstraZeneca, BMS, Daiichi Sankyo, G1, Jazz, MonteRosa, Roche/Genentech Paid Consulting: Catalyst, Kisoji, STCube.
